Single-Cell Antibody Discovery
Empowering Your Discovery with
Precision, Speed, and Confidence
Unlock the future of antibody discovery with our cutting-edge single-cell technology. Our platform enables the precise identification and isolation of high-affinity antibodies directly from individual B-cells, accelerating the path from discovery to development.
Let’s drive the development of transformative therapies together
With single-cell antibody discovery, we unlock unprecedented specificity, speed, and therapeutic potential of your project
Unparalleled Precision
Isolates antibodies directly from individual B-cells, ensuring highly specific targeted discoveries.
Rapid Discovery
Speeds up the path from identification to development, streamlining therapeutic antibody discovery.
High Diversity Capture
Maximizes the discovery of unique, high-affinity antibodies by analysing vast antibody repertoires.
Enhanced Accuracy
Reduces off-target effects, improving the chances of identifying effective candidates.
Optimized for Complex Targets
Excels at discovering antibodies for challenging targets.
Going Beyond Simple Antibody Hit Generation Discovery
Accelerate your antibody discovery and characterization using the innovative bloom assay quantification on the optofluidic system.
This system enables ranking thousands of antibody hits based on relative affinity, significantly reducing the timeline compared to traditional re-expression and characterization workstreams.
Antibody Discovery Multispecies Screening Capabilities
Discovery Workflow from Sample to Sequence in 1 Week
The Opto Memory B Discovery workflow enables rapid isolation and activation of memory B cells, function forward single B cell screening, and recovery of monoclonal antibody sequences in a single week.
Adapted from: Going Beyond Simple Antibody Hit Generation in Opto® B Discovery with Relative Affinity Ranking for Soluble Antigens Brochure. 2023 Bruker Corporation
Rapid and Quantified Assay Results
Within minutes, the system identifies antibody hits, quantifies the captured antibodies, and calculates fluorescence-based relative Beacon Affinity Scores. Once antibody-secreting cells are isolated, researchers can perform a customizable on-chip assay using species-specific IgG capture beads and fluorescently labeled antigens.
Adapted from: Accelerating CAR and TCR Discovery with Single-Cell Functional Screening. 2023 Bruker Corporation
Validated Relative
Affinity Rankings
Opto® B Discovery Affinity Assay
is a revolutionary tool
It enables rapid, high-throughput ranking of antibody hits, expediting discovery while improving downstream success rates. The assay has been validated against industry-standard techniques such as biolayer interferometry (BLI), ensuring reliable and accurate affinity rankings at an unprecedented scale.
Isolate and produce antibodies with unmatched target specificity, ideal for precision therapeutics.
Empower ArtificialIntelligence based Antibody Discovery
It enables rapid, high-throughput ranking of antibody hits, expediting discovery while improving downstream success rates.
The assay has been validated against industry-standard techniques such as biolayer interferometry (BLI), ensuring reliable and accurate affinity rankings at an unprecedented scale.
UMAP Visualization of VEGFR2-targeting Antibody Sequences
Each point represents an individual antibody amino acid sequence, colored by Beacon Affinity Score (blue-to-yellow gradient). Stars indicate antibodies with BLI validated affinities: yellow (KD <1 nM), gray (KD 1-10 nM), blue (KD >10 nM). This visualization enables exploration of sequence diversity, affinity clustering, and selection of optimal antibody candidates.
Human IgG
Single-Cell Antibody Discovery
Human Immunoglobulin G (IgG) plays a critical role in the immune response, making it a prime target in antibody discovery. Using single-cell technology, we can precisely identify and isolate high-affinity IgG antibodies from individual B-cells. This innovative approach accelerates the discovery of unique IgG antibodies, optimizing the development of targeted therapies for infectious diseases, autoimmune disorders, and cancer. With single-cell antibody discovery, we unlock unprecedented specificity, speed, and potential for therapeutic advancement.
Rabbit antibodies have high affinity and the ability to recognize unique epitopes, often outperforming other species' antibodies in specificity and binding strength. Single-cell antibody discovery technology enhances this advantage by isolating rabbit IgG antibodies at the individual B-cell level, enabling rapid and precise identification of potent candidates. Combining rabbit IgG's unique properties with single-cell precision drives highly targeted antibody discovery breakthroughs.
Rabbit IgG
Single-Cell Antibody Discovery
Mouse IgG
Single-Cell Antibody Discovery
Single-cell antibody discovery technology enables the isolation of specific mouse IgG antibodies from individual B-cells, allowing for a highly targeted approach that preserves native antibody diversity. This precision speeds up the discovery of high-affinity antibodies, particularly valuable for creating models in immunology, cancer, and infectious disease research. By combining the reliable specificity of mouse IgG with single-cell technology, we advance the generation of antibodies for both research and therapeutic applications.
Camelid IgG
Single-Cell Antibody Discovery
Camelid antibodies, particularly known for their single-domain structure, offer exceptional stability and the ability to bind unique, hidden epitopes that conventional antibodies may miss. This approach is invaluable for developing antibodies against complex targets in areas such as cancer, neurodegenerative diseases, and infectious diseases. By merging camelid IgG’s unique structure with single-cell precision, we unlock new potential for targeted, flexible, and resilient antibody therapeutics.